Vilin Bio Med Limited (NSE: VILINBIO) is a Hyderabad, Telangana-based company in the Pharmaceuticals industry. With a market capitalisation of ₹79 Cr, it ranks #3,425 by market cap among the 6,197 Indian listed companies on FinBizNet, and #46 of 63 in Pharmaceuticals. At ₹52.00 (as of 16 Nov 2026), the share price is 14.7% below its 52-week high of ₹60.95 and 174.4% above its 52-week low of ₹18.95. The share price is up 99.6% over one year and up 26.3% over three months.
| Current Price | ₹52.00 |
|---|---|
| Market Cap | ₹79 Cr |
| NSE Symbol | VILINBIO |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 41.3 |
| Return on Equity | 7.51% |
| Return on Assets | 5.80% |
| 52-Week Range | ₹18.95 – ₹60.95 |
| 1-Year Price Change | +99.6% |
| 3-Month Price Change | +26.3% |
| Beta (1Y) | 0.52 |
| Headquarters | Hyderabad, Telangana |
| Website | www.vilinbiomed.co.in |
Promoters held 56.65% of Vilin Bio Med Limited's shares as of Jun 2026, against 63.89% in Sept 2025 (−7.24 percentage points).
Vilin Bio Med Limited engages in the manufacture and trade of pharmaceutical products in India. It provides cardiovascular, musculo-skeletal, antibiotic, central nervous system, alimentary system, genito-urinary tract, respiratory system and anti-allergic, anti- diabetic, liquid orals, and miscellaneous drugs, as well as multi-vitamins, minerals, and amino acids supplements. The company offers its products in the form of oral liquids, dry syrups, sachets, external preparations, beta and non beta lactam tablets and capsules, and nutritional food supplements. It sells its products in bulk to pharmaceuticals manufacturers, marketers, and traders. Vilin Bio Med Limited was incorporated in 2005 and is based in Hyderabad, India.
1. Pharmaceuticals-This segment manufactures and sells pharmaceutical products. 2. NA-NA 3. NA-NA 4. NA-NA
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Vilin Bio Med Limited | ₹79 Cr | 41.3 | 7.51% | — | +99.6% |
Listed by market capitalisation. Ratios are shown for context only.
Vilin Bio Med Limited is trading at ₹52.00, with a market capitalisation of ₹79 Cr.
Vilin Bio Med Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Vilin Bio Med Limited has a P/E of 41.3 and a return on equity of 7.51%.
Vilin Bio Med Limited is listed on the NSE under the symbol VILINBIO.
Vilin Bio Med Limited's share price is up 99.6% over one year and up 26.3% over three months. Its 52-week range is ₹18.95 to ₹60.95.
Promoters held 56.65% of Vilin Bio Med Limited's shares as of Jun 2026, against 63.89% in Sept 2025 (−7.24 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.